TREA

97920385 - A

Follow

Information

  • Trademark
  • 97920385
  • Serial Number
    97920385
  • Filing Date
    May 04, 2023
    2 years ago
  • Transaction Date
    April 23, 2025
    8 months ago
  • Status Date
    April 22, 2025
    8 months ago
  • Published for Opposition Date
    August 27, 2024
    a year ago
  • Location Date
    October 22, 2024
    a year ago
  • First Use Anywhere Date
    October 18, 2013
    12 years ago
  • First Use In Commerce Date
    October 18, 2013
    12 years ago
  • Status Code
    730
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    MURRAY, TY
  • Attorney Docket Number
    062994-400
    Attorney Name
    Karen Won
    Law Office Assigned Location Code
    M40
  • Owners
Information
Mark Drawing Code
3
Mark Identification
A
Case File Statements
  • DM0000: The mark consists of a circle with an "A" inside, with the horizontal line of the "A" having been replaced by a dot.
  • GS0051: Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders
  • PM0001: ACUITAS
  • CC0000: Color is not claimed as a feature of the mark.
  • GS0451: Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology
  • GS0011: Lipids used in the manufacture of cosmetics, beverages, food products and food supplements, lipid nanoparticles used in the manufacture of cosmetics, beverages, food products, and food supplements, lipid formulations used in the manufacture of cosmetics, beverages, food products, and food supplements; nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use
  • GS0421: Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids, lipid formulations, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, and nucleic acid therapeutics; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, vaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology
Case File Event Statements
  • 5/8/2023 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 6/2/2023 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/16/2024 - a year ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 6/3/2023 - 2 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSM
  • 1/26/2024 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/26/2024 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 1/26/2024 - a year ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 1/26/2024 - a year ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/12/2024 - a year ago
    11 - FINAL REFUSAL WRITTEN Type: CNFR
  • 4/16/2024 - a year ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/16/2024 - a year ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/12/2024 - a year ago
    13 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 7/18/2024 - a year ago
    14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 5/12/2024 - a year ago
    12 - FINAL REFUSAL E-MAILED Type: GNFR
  • 7/18/2024 - a year ago
    16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 7/18/2024 - a year ago
    17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 7/18/2024 - a year ago
    18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/18/2024 - a year ago
    15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 8/7/2024 - a year ago
    19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/18/2024 - a year ago
    23 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 10/18/2024 - a year ago
    24 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 10/22/2024 - a year ago
    22 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 8/27/2024 - a year ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/27/2024 - a year ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 10/18/2024 - a year ago
    25 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 12/17/2024 - a year ago
    28 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 12/17/2024 - a year ago
    29 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 12/17/2024 - a year ago
    27 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 12/17/2024 - a year ago
    30 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 4/22/2025 - 8 months ago
    31 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 4/22/2025 - 8 months ago
    32 - SOU EXTENSION 1 FILED Type: EXT1
  • 4/22/2025 - 8 months ago
    33 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 4/22/2025 - 8 months ago
    34 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 12/17/2024 - a year ago
    26 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR